Zimmer Biomet Holdings, Inc. (ZBH) Cash Flow Statement

The persistent gap between net income and operating cash flow appears largely driven by substantial non-cash depreciation and amortization charges related to the company's extensive field inventory and surgical instrument sets. Investors should monitor whether this high conversion quality remains sustainable as the company shifts toward more capital-intensive robotic platforms.

The fluctuation in FCF margins suggests that while the underlying business is cash-generative, the timing of inventory investments and surgical set deployments creates lumpy cash flow profiles. This volatility warrants further investigation into whether the company can achieve more predictable FCF conversion as it scales its newer product lines.

This recurring working capital drag highlights the structural necessity of holding significant inventory to ensure surgeon readiness, which effectively ties up cash that might otherwise be available for debt reduction or shareholder returns. The efficiency of this inventory management remains a critical lever for improving the company's overall cash flow profile.

The company's willingness to deploy substantial cash toward both inorganic growth and shareholder returns suggests a management team confident in the long-term cash-generating potential of its orthopedic portfolio. However, the reliance on external acquisitions to drive growth may indicate that internal R&D efforts are not yet sufficient to sustain the desired competitive trajectory.